Abortive Treatment of Migraine With the Cefaly® Abortive Program Device: Pilot Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 2
- 主要终点
- Pain Freedom (PF) at 2 Hours
研究概览
简要总结
The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This open clinical trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device, prior to development of a sham-controlled trial.
详细描述
The main objective of this study is to have a pilot assessment of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack, as triptans are generally used. That is to say having pilot data to assess the efficacy of the Cefaly® Abortive Program device in the abortive treatment of acute migraine as measured by 2-hour pain freedom, pain relief and migraine associated symptoms freedom, plus evolution of these measurements for 24 hours after the beginning of the treatment session.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age from 18 to 65 years on the day of signing the informed consent form
- •≥ 1-year history of migraine with or without aura according to the diagnostic criteria listed in the International Classification of Headache Disorders (ICHD)-III beta (2013) section 1, migraine (8), with the exception of aura without headache, hemiplegic migraine and brainstem aura migraine
- •Migraine onset before the age of 50 years
- •Having between 2 and 8 moderate or severe migraine attacks (Grade 2 or 3) per month in each of the two months prior to screening
- •Patient understands the study procedures, alternative treatments available, and voluntarily agrees to participate in the study by giving written informed consent
- •Patient is able to read and understand the written information (instruction sheet, paper diary and Adverse Events (AE) collecting form)
排除标准
- •Patient has difficulty distinguishing his/her migraine attacks from tension-type headaches
- •Patient has more than 15 headache days per month
- •Patient having received supraorbital nerve blocks in the prior 4 months
- •Patient having received Botox treatment in the prior 4 months
- •Modification of a migraine prophylaxis treatment in the previous 3 months
- •Diagnosis of other primary headache disorders, except rare (< 4) tension-type headaches per month
- •Diagnosis of secondary headache disorders included Medication Overuse Headache
- •Patients abusing opioids or user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence
- •Implanted metallic or electronic device in the head
- •Cardiac pacemaker or implanted or wearable defibrillator
- •Patient having had a previous experience with the Cefaly® device
- •Migraine Aura without headache
- •Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of screening visit (Visit 1)
- •Patients not having the ability to use appropriately the device and/or to perform themselves or bear the first 20-minute stimulation session during the training session at the study site
结局指标
主要结局
Pain Freedom (PF) at 2 Hours
时间窗: 2 hours
The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.
Most Bothersome Migraine-associated Symptom (MBS) Freedom at 2 Hours
时间窗: 2 hours
The percentage of patients with absence, at 2 hours after the beginning of the e-TNS session, of the most bothersome migraine-associated symptom identified at baseline.
次要结局
- Use of Rescue Medication Between 2 and 24 Hours(Between 2 and 24 hours)
- Migraine-associated Symptoms Freedom at 2 Hours(2 hours)
- Sustained Pain Freedom at 24 Hours(24 hours)
- Pain Relief (PR) at 2 Hours(2 hours)